drugset / Trial / NCT00614926

Modafinil for Treatment of Fatigue in ALS Patients

NCT00614926

Phase 4 Completed 32 enrolled New York State Psychiatric Institute
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this pilot study is to evaluate whether modafinil is helpful in alleviating fatigue, low energy, drowsiness and difficulty concentrating among patients with amyotrophic lateral sclerosis (ALS), and to evaluate incidence and frequency of adverse events, if any.

Timeline

Start
2006-06
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 100 mg
Subject Modafinil Small molecule 300 mg

Indications

No indication recorded.